Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Pliant places IPO terms
Existing investor Novartis has committed to a $10m private placement alongside the IPO, in which the fibrosis therapy developer, based on UCSF research, is set to raise up to $96m.
Nanoform to shape $76.7m IPO
Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.
Passage Bio pushes proceeds to $248m
Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.
Cambricon clambers for public listing
Chinese Academy of Sciences and its VC subsidiary TCL Capital are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.
Passage Bio takes $216m IPO journey
University of Pennsylvania-linked Passage Bio issued 4.6 million more shares than originally planned to raise $216m, up more than 70% on its $125m original target.
Stayble stacks up $3.6m IPO
The Chalmers University of Technology back pain injection spinout floated in an IPO that was oversubscribed by more than four-fold.
Revolution hits public markets in $238m IPO
The precision cancer therapy developer, based on research from several universities, floated at the top of an upsized range and saw its price continue to rise post-IPO.
Beam Therapeutics brings IPO to $207m close
The genomic drug developer, spun out of Harvard University, has completed its initial public offering, boosting its size from $180m to $207m.

Other News

Beam Therapeutics shines in $180m IPO
Genomic medicine developer Beam will raise $180m in a upsized initial public offering three years after being spun out of Harvard University.
Monivent nears $2.1m IPO
Chalmers University of Technology-founded baby ventilation monitor developer Monivent will join the Spotlight Stock Market in an IPO where 60% of shares have advance subscriptions in place.
Passage Bio reaches IPO stage
University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.
Revolution to make waves with IPO
The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.
Revolution Medicines to rule with $100m IPO
Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.
Cabaletta captures $74.8m IPO
University of Pennsylvania spinout Cabaletta has gone public after raising $74.8m in an initial public offering on the Nasdaq Global Select Market.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg